Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Here's Why Nektar Therapeutics Fell as Much as 10.8% Today

By Maxx Chatsko - Jul 25, 2019 at 3:47PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A drug candidate was oh-so-close to a regulatory decision, but next month's meeting has been delayed indefinitely.

What happened

Shares of Nektar Therapeutics ( NKTR 9.51% ) dropped nearly 11% today after the company reported that the U.S. Food and Drug Administration (FDA) was delaying a previously scheduled advisory committee meeting for NKTR-181. The development was quietly reported in an 8-K filed with the U.S. Securities and Exchange Committee and didn't have an accompanying press release, which may have made the news easy to miss and the drop appear to have come out of nowhere.

That said, the decision to delay the advisory committee meeting had nothing to do with Nektar Therapeutics or any factor unique to NKTR-181. Rather, the FDA is postponing all such meetings for drug candidates that are opioid analgesics as it reevaluates how it deals with opioid drugs. 

As of 3:13 p.m. EDT, the stock had settled to a 7.3% loss.

A finger tracing a declining chart on a touchscreen.

Image source: Getty Images.

So what

An advisory committee meeting allows experts from across the scientific community to help regulators weigh the pros and cons of an experimental drug that's up for review. It's one of the last regulatory meetings that takes place before a drug candidate earns (or is denied) marketing approval from the FDA. Case in point: The advisory committee meeting for NKTR-181 was scheduled on August 21 -- just eight days before regulators were due to make their final decision on the drug.

Those dates have now been pushed back indefinitely. While that's not ideal, investors can't be too surprised, given the ongoing opioid crisis and recent reports detailing the awful and complicated reality of the whole mess. 

To be fair, NKTR-181 was designed to selectively target opioid receptors in the nervous system. That allows the drug candidate to provide pain relief without causing euphoria, which the company says should reduce the potential for abuse and addiction. Whether or not the drug candidate gets swept up in new FDA guidelines for opioids -- if regulators create new guidelines at all -- can't be known at this time. 

Now what

Despite the nuance required to accurately assess today's development, investors are more concerned with how the delay will impact a reeling pipeline at Nektar Therapeutics. The company has already struggled to communicate its new strategy to investors and show tangible signs of progress with its latest pivot. Pushing back the possible market launch of NKTR-181 doesn't help one bit.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Nektar Therapeutics Stock Quote
Nektar Therapeutics
NKTR
$11.86 (9.51%) $1.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/07/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.